Half Year Shareholder Update
Telix Pharmaceuticals Limited Announces Half-year Shareholder...
Read moreLatest News
Category: ASX
AUDIO LINK NOT ATTACHED – Telix Half-Year Results 2021 and Company Update Conference Call
Telix announces Half-Year Results 2021 and provides shareholder...
Read more
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Telix releases details of two ancillary studies under the ProstACT program, including a Phase II study in collaboration with...
Read more
Telix H1 2021 Results and Company Update Conference Call
Telix to hold investor conference call to present H1 2021 financial results and Company...
Read more
Activities Report and Appendix 4C for June 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...
Read more
Telix Update on FDA New Drug Application Review for Illuccix®
Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product...
Read more
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA...
Read more
Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging
Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68...
Read more
Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging
Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German...
Read more
Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses
Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of...
Read more